Ropinirole (ropinirole): Reviews and patient testimonials

Ropinirole 0.25 mg Film-Coated Tablets

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see Section 5.1).

Ropinirole 0.25mg Film coated Tablets

Treatment of Parkinson's disease under the following conditions:

Initial treatment as monotherapy, in order to delay the introduction of levodopa.

In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole 0.5 mg Film-Coated Tablets

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see Section 5.1).

Ropinirole 0.5 mg Film-coated Tablets

For the treatment of Parkinson's disease under the following conditions:

• Initial treatment as monotherapy, in order to delay the introduction of levodopa

• In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

For the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole 0.5mg Film coated Tablets

Treatment of Parkinson's disease under the following conditions:

Initial treatment as monotherapy, in order to delay the introduction of levodopa.

In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole 1 mg Film-Coated Tablets

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see Section 5.1).

Ropinirole 1 mg Film-coated Tablets

For the treatment of Parkinson's disease under the following conditions:

• Initial treatment as monotherapy, in order to delay the introduction of levodopa

• In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

For the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole 1mg Film coated Tablets

Treatment of Parkinson's disease under the following conditions:

Initial treatment as monotherapy, in order to delay the introduction of levodopa.

In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole 2 mg Film-Coated Tablets

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see Section 5.1).

Ropinirole 2 mg Film-coated Tablets

For the treatment of Parkinson's disease under the following conditions:

• Initial treatment as monotherapy, in order to delay the introduction of levodopa

• In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

For the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole 2mg Film coated Tablets

Treatment of Parkinson's disease under the following conditions:

Initial treatment as monotherapy, in order to delay the introduction of levodopa.

In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations)

Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome

Ropinirole Mylan XL 2 mg prolonged-release tablets

Treatment of Parkinson's disease under the following conditions:

- Initial treatment as monotherapy, in order to delay the introduction of levodopa.

- In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations).

Ropinirole Mylan XL 4 mg prolonged-release tablets

Treatment of Parkinson's disease under the following conditions:

- Initial treatment as monotherapy, in order to delay the introduction of levodopa.

- In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations).

Route of administration: Oral
Molecule: ropinirole